Eterna Therapeutics Files 8-K on Shareholder Nominations
Ticker: ERNAW · Form: 8-K · Filed: Feb 13, 2025 · CIK: 748592
| Field | Detail |
|---|---|
| Company | Eterna Therapeutics Inc. (ERNAW) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, shareholder-nomination, corporate-action
TL;DR
Eterna Therapeutics filed an 8-K about shareholder nominations - board shakeup incoming?
AI Summary
Eterna Therapeutics Inc. filed an 8-K on February 13, 2025, reporting shareholder nominations for its upcoming meeting. The filing indicates that the company, formerly known as Brooklyn ImmunoTherapeutics, Inc., is incorporated in Delaware and has its principal executive offices in Cambridge, MA.
Why It Matters
This filing signals potential changes in the company's board composition, which could impact its strategic direction and governance.
Risk Assessment
Risk Level: medium — Shareholder nominations can indicate activism or dissatisfaction, potentially leading to changes in company strategy or leadership.
Key Players & Entities
- Eterna Therapeutics Inc. (company) — Registrant
- Brooklyn ImmunoTherapeutics, Inc. (company) — Former Company Name
- February 7, 2025 (date) — Earliest event date
- February 13, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, MA (location) — Principal Executive Offices
FAQ
What is the specific purpose of the shareholder nominations mentioned in the 8-K?
The 8-K filing indicates shareholder nominations pursuant to Exchange Act Rule 14a-11, suggesting these nominations are related to director elections or other governance matters at an upcoming shareholder meeting.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 7, 2025.
What is Eterna Therapeutics Inc.'s former company name?
Eterna Therapeutics Inc.'s former company name was Brooklyn ImmunoTherapeutics, Inc., with a date of name change on March 25, 2021.
Where are Eterna Therapeutics Inc.'s principal executive offices located?
Eterna Therapeutics Inc.'s principal executive offices are located at 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141.
What is the SIC code for Eterna Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Eterna Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 596 words · 2 min read · ~2 pages · Grade level 15.5 · Accepted 2025-02-13 16:30:17
Key Financial Figures
- $0.005 — ch registered Common Stock, par value $0.005 per share ERNA The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 32KB
- 0001493152-25-006446.txt ( ) — 203KB
- erna-20250207.xsd (EX-101.SCH) — 3KB
- erna-20250207_lab.xml (EX-101.LAB) — 33KB
- erna-20250207_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. On February 7, 2025, the board of directors of Eterna Therapeutics Inc. (the "Company") set the date for the Company's 2025 annual meeting of stockholders (the "Annual Meeting") for May 1, 2025, which is more than 30 calendar days before the one-year anniversary of the Company's 2024 annual meeting of stockholders. In light of the foregoing, and in accordance with the Company's second amended and restated bylaws (the "Bylaws"), in order for any business to be brought before the Annual Meeting by a stockholder and for any person to be nominated for election to the Company's board of directors at the Annual Meeting by a stockholder, such stockholder must notify the Company of such intention by notice received at the Company's principal executive offices not later than the close of business on February 23, 2025. Stockholder proposals intended for inclusion in the Company's proxy statement for the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), must be received at the Company's principal executive offices no later than the close of business on February 23, 2025, which the Company believes is a reasonable time before it begins to print and mail proxy materials for the Annual Meeting. In addition, all such stockholder notices and stockholder proposals must conform to the applicable requirements of the Bylaws, the rules and regulations promulgated under the Exchange Act and other applicable law. All such notices and stockholder proposals are be directed to: Eterna Therapeutics Inc., Attention: Secretary, 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Eterna Therapeutics Inc. Dated: February 13, 2025 By: /s/ Sanjeev Luther Sanjeev Luther Preside